RICHMOND, Calif., Sept. 12, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to ...

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted ...

Public speaking can be a challenge for many people. A successful event in which you are showcased as the public speaker can be a feather in your cap. Implement several specific strategies to have a ...

We’ve all sat through our share of boring presentations. It’s mind-numbing to be forced to listen to dry content that’s delivered (or worse, read) at us, rather than discussed with us. Often, all this ...

Studies have shown that humans cannot simultaneously learn opposing force fields or opposing visuomotor rotations, even when provided with arbitrary contextual information, probably because of ...

The National Volunteer Fire Council has extended its deadline to Nov. 2 for presentation proposals for it Training Summit in 2026.

Science debates and presentations are a powerful way to ignite curiosity, boost communication skills, and enhance critical thinking among school students. Whether in a classroom setting or a formal ...

Single-doses of AB-729 studied to date, 60 mg, 90 mg and 180 mg, resulted in comparable mean HBsAg declines at week 12, followed by a sustained plateau phase. During the multiple-dose portion of the ...